Moreover, upregulated expression of DA receptor D2 (DRD2) is associated with elevated malignant potential of gastric cancer and PDAC, implicating a therapeutic merit of antagonizing DRD2 in these tumors [120,121]. This evidence concerns the gene DRD2 and gastric cancer.